Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

FDA Approves Kerendia for Adults With Type 1 Diabetes and Kidney Disease

18 September 2026 · By · Wire by Fusion42

Published

18 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at webmd.com →

◆ Verified

Fusion42 · 18 September 2026 · Fusion42 review

The FDA has approved Kerendia for adults with chronic kidney disease linked to type 1 diabetes, marking the first approval specifically for this patient group. The approval is based on clinical trial results showing significant reduction in urine protein levels, which indicate lower risk of kidney failure.

This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 17 Sep 2026 and 18 Sep 2026.

◆ ◆ The Wire takeaway

The FDA opening up this market segment with Kerendia means you can now target treatment solutions specifically for type 1 diabetes kidney disease patients, an area previously underserved by approved drugs.

◆ Coverage

3 sources · first reported 17 Sep 2026 · latest 18 Sep 2026

◆ Related on Wire

◆ Topics

Biotechfda-approvaltype-1-diabeteskidney-diseaseclinical-trialkerendia